TheraRadar
← Back
Data updated: Jun 28, 2026

HELSINN

Pharma
OncologyGastroenterology Execution: Excellent

HELSINN is a pharmaceutical company focused on Oncology, Gastroenterology. Key products include VALCHLOR.

2013
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

HELSINN at a Glance

  • Strong track record with 86% execution quality across 25 trials
  • Fast trial execution (16 months median completion)

HELSINN's Key Drugs

HELSINN's core commercial portfolio centers on VALCHLOR, spanning Oncology and Gastroenterology — its most strategically important drugs approved in the last 15 years.

VALCHLOR
Oncology

Mycosis Fungoides

Approved 2013

HELSINN's Recent FDA Approvals

New NDA/BLA approvals for HELSINN over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

HELSINN's Therapeutic Areas

HELSINN's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Gastroenterology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 95%
1 drugs Phase 3: 6 Phase 2: 2 Phase 1: 1
Gastroenterology 5%
0 drugs Phase 2: 1

HELSINN's Top Competitors

HELSINN's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Bristol-Myers Squibb, and Takeda. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Johnson & Johnson big-pharma
Oncology, Gastroenterology
Bristol-Myers Squibb big-pharma
Oncology, Gastroenterology
Takeda big-pharma
Gastroenterology, Oncology
PF PRISM CV big-pharma
Oncology, Gastroenterology
ASTELLAS specialty
Oncology, Gastroenterology

HELSINN Pipeline Snapshot

HELSINN has 10 active clinical programs from ClinicalTrials.gov — 6 Phase 3, 3 Phase 2 and 1 Phase 1.

6
Phase 3
3
Phase 2
1
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • VALCHLOR leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Oncology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 11/12 completed
  • • Speed: 16 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges